Science 37 to Report First Quarter 2022 Financial Results on May 9, 2022
04/25/2022 - 07:55 AM
RESEARCH TRIANGLE PARK, N.C., April 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report first quarter 2022 financial results before the market opens on Monday, May 9, 2022. Company management will host a corresponding conference call at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by dialing (844) 467-7754 for domestic callers or (270) 215-9366 for international callers, followed by Conference ID: 1388417. A live and archived webcast of the event will be available on the Investor Relations section of the Science 37 website at https://investors.science37.com/ .
About Science 37
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Agile Clinical Trial Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com
Contacts:
MEDIA INQUIRIES: pr@science37.com
INVESTOR RELATIONS :investors@science37.com
SNCE Rankings
#5224 Ranked by Stock Gains
SNCE Stock Data
Industry
Testing Laboratories
Sector
Professional, Scientific, and Technical Services
About SNCE
science 37 uses advanced telemedicine technology and patient-centric innovative networked clinical research models to rapidly accelerate biomedical discovery and bring down the costs of clinical trials. in addition to our own researchers, we also work closely with top physician-scientists and leading telemedicine companies. s37 offers full support and end-to-end services for networked clinical trials. if you are an investigator, an inventor, a small biotech company or a large pharmaceutical company, we can help you achieve your clinical trial goals faster and easier than ever before. based in los angeles, we are focused on the development of networked patient-centric models for clinical research to rapidly accelerate biomedical discovery. we leverage partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups, virtual e-consenting, mobile devices, and other technology companies to maximize efficiency. then, using design-thinking principles and rapid pr
